Coiled Therapeutics (AIM:COIL) executive chair Dr Sotirios Stergiopoulos and CEO Sridhar Vempati talked with Proactive's Stephen Gunnion about promising clinical results for its lead oncology candidate AO-252. The discussion highlighted a significant improvement in clinical outcomes, with the company reporting an increase in clinical benefit rate from 40% to 80% following a shift to twice-daily dosing.
Vempati explained that the enhanced efficacy appears linked to sustained drug exposure, noting that maintaining therapeutic levels for longer durations helps drive stronger results. He also emphasised AO-252’s multimodal mechanism, targeting mitosis, DNA damage repair, and immune activation. This approach not only attacks tumours directly but may also help the immune system recognise and respond to cancer more effectively.
Stergiopoulos highlighted the importance of these findings in heavily pre-treated patients, many of whom had exhausted available treatment options. He said: “The fact that we’re seeing effect is really astounding… and it gives us every confidence that we are on the right path.” The ability to generate responses in such late-stage cases suggests potential for even greater efficacy in earlier treatment lines.
The company is now advancing plans for combination trials and new formulations, with multiple data readouts expected throughout 2026. AO-252’s favourable safety profile and synergy with existing therapies could expand its use across a wide range of cancer indications.
For more insights like this, visit Proactive’s YouTube channel, give this video a like, subscribe, and turn on notifications so you never miss an update.
#CoiledTherapeutics #AO252 #CancerResearch #Oncology #Biotech #ClinicalTrials #DrugDevelopment #Immunotherapy #CancerTreatment #HealthcareInnovation #Biopharma #PrecisionMedicine
